Christoph Wandel
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Pharmacological Effects and Toxicity Studies, Pharmacogenetics and Drug Metabolism, Anesthesia and Sedative Agents, Epilepsy research and treatment
Most-Cited Works
- → Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein(1999)459 cited
- P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.(1999)
- → CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism(2000)247 cited
- → Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein(2002)213 cited
- → Midazolam is metabolized by at least three different cytochrome P450 enzymes(1994)155 cited
- → Morbidity and medication in a large population of individuals with Down syndrome compared to the general population(2015)141 cited
- → AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial(2024)128 cited
- → A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder(2019)124 cited
- → Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR)(2023)85 cited
- → A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome(2022)42 cited